共 91 条
BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients
被引:34
作者:
Colle, Romain
[1
]
Deflesselle, Eric
[1
]
Martin, Severine
[1
]
David, Denis J.
[2
]
Hardy, Patrick
[1
]
Taranu, Adela
[1
]
Falissard, Bruno
[3
]
Verstuyft, Celine
[4
,5
]
Corruble, Emmanuelle
[1
]
机构:
[1] Hop Bicetre, AP HP, INSERM UMR Team Depress & Antidepressants 1178, Fac Med Paris Sud,Serv Psychiat, F-94275 Le Kremlin Bicetre, France
[2] Fac Pharm Paris, INSERM UMR Team Depress & Antidepressants 1178, Chatenay Malabry, France
[3] Hop Paul Brousse, AP HP, INSERM UMR 1178, Fac Med Paris Sud,Dept Biostat, F-94400 Villejuif, France
[4] Univ Paris 11, Hop Bicetre, AP HP,Serv Genet Mol Pharmacogenet & Hormonol, INSERM Immunol Malad Virales & Autoimmues, F-94275 Le Kremlin Bicetre, France
[5] Univ Paris 11, INSERM U1184, F-92296 Chatenay Malabry, France
关键词:
antidepressant remission;
antidepressant response;
BDNF;
major depressive disorder;
major depressive episode;
PNTR75;
single nucleotide polymorphism;
TRKB;
NEUROTROPHIC FACTOR GENE;
GENOME-WIDE ASSOCIATION;
VAL66MET POLYMORPHISM;
MAJOR DEPRESSION;
FACTOR BDNF;
TREATMENT RESPONSE;
GLUCOCORTICOID-RECEPTOR;
SEROTONIN TRANSPORTER;
SEQUENCE VARIATIONS;
BRAIN;
D O I:
10.2217/pgs.15.56
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
We propose an extensive review of the literature about BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients. Five genome-wide association studies and 30 association studies were included. Twenty seven studies focused on the Val66Met polymorphism (rs6265), the Met allele being associated with a higher antidepressant efficacy only in Asian patients. Other BDNF/TRKB/P75NTR polymorphisms (BDNF: rs7103411, rs7124442, rs908867, rs2049046, rs61888800, rs10501087, rs1491850; TRKB: rs10868223, rs11140778, rs1565445, rs1659412; P75NTR: rs2072446) were reported to be associated with antidepressant efficacy but these results were not replicated. Finally, there are 15 positive studies among 30 studies regarding BDNF/TRKB/P75NTR polymorphisms. The only SNP which benefits of at least three positive studies is the BDNF Val66Met polymorphism (rs6265). Consequently, with a lack of good and consistent studies, the clinical utility of BDNF in treatment selection is far from clear. We propose several recommendations for further studies.
引用
收藏
页码:997 / 1013
页数:17
相关论文